GENinCode PLC ShareSoc investor presentation

TIDMGENI

GENinCode PLC

12 October 2023

GENinCode Plc

("GENinCode" or the "Company")

ShareSoc investor presentation

Presentation at ShareSoc & Walbrook PR Healthcare Companies Hybrid Event

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces that Matthew Walls, CEO will provide a live presentation to investors at the ShareSoc & Walbrook PR Healthcare Companies Hybrid Event on Thursday 19 October 2023.

The event will start at 5pm, with registration at 4.30pm and will take place in London at ISH Venues, 1 Park Crecent, W1B 1SH. All attendees, both in-person and virtual, will have the opportunity to ask questions and those attending the seminar will be able to network with company directors and fellow investors over drinks and a buffet. No new material information will be disclosed in the presentation.

To register for the event and for further details, please click on the following link .

For more information visit www.genincode.com

Enquiries:

 
 GENinCode Plc                                                           www.genincode.com or via Walbrook PR 
 Matthew Walls, CEO 
 Paul Foulger, CFO 
 
 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                             Tel: [phone] 
 Alex Price / Ben Maddison / Richard Short 
 
 Cavendish Securities Plc (Joint Broker)                                             Tel: [phone] 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 
 Walbrook PR Limited 
  Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage           Tel: [phone] or [e-mail] 
 
 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.

About Cardiovascular Disease (CVD):

CVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas with the NHS 10 Year Plan identifying CVD as the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

Early detection and treatment of CVD can help patients live longer, healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year Plan is working towards people knowing and managing risks around their 'ABC' (AF, Blood pressure and Cholesterol).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFFLFWFEDSEIS

(END) Dow Jones Newswires

October 12, 2023 02:00 ET (06:00 GMT)